Curis is conducting clinical trials to evaluate the efficacy and safety of an investigational drug (CA-4948) in cancer. All currently enrolling clinical trials for emavusertib (CA-4948) can be found on clinicaltrials.gov.
Sponsored
A Study of CA-4948 in Patients With Relapsed or Refractory Primary Central Nervous System Lymphoma
A Study of Emavusertib + An Approved Bruton Tyrosine Kinase Inhibitor (BTKi) in Participants With Chronic Lymphocytic Leukemia (CLL) and Other B-cell Malignancies
